12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Company News  |  Deals

Quark, Pfizer deal

Quark and Pfizer amended a 2006 deal granting the pharma exclusive, worldwide rights to PF-655. Under the amendment, Quark will conduct a Phase IIa trial to evaluate PF-655 in patients with...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >